1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Premature Ejaculation Therapeutics Market - Global Outlook and Forecast 2020-2025

Premature Ejaculation Therapeutics Market - Global Outlook and Forecast 2020-2025

  • April 2020
  • 269 pages
  • ID: 5730664
  • Format: PDF
  • Arizton
Up to $1100 off Until Jun 10th 2020

Summary

Table of Contents

Search Inside

Get an in-depth analysis of COVID-19 impact on the global premature ejaculation market.

The premature ejaculation therapeutics market is expected to grow at a CAGR of over 8% during the period 2019–2025.

The global premature ejaculation (PE) therapeutics market is expected to grow at a steady CAGR during the forecast period. The market growth can be mainly attributed to the growing prevalence of premature ejaculation (PE) among men globally. PE is the most prevalent sexual dysfunction among men world over. With the presence of a single approved oral drug, the PE therapeutics market is dominated by off-label drugs, generic versions of patent expired drugs, and OTC formulations, both regionally as well as globally. The increasing demand for several off-label and generic drugs is a primary factor driving the growth of the market. The treatment with off-label drugs belonging to SSRIs and topical formulations has revolutionized the treatment approach. Several vendors are offering off-label drugs that belong to different drug classes such as SSRIs and PDE5 inhibitors and OTC topical creams/sprays for treatment. Therefore, the demand for such drugs is likely to increase at a steady rate globally.

Another advance is the advent of metered-dose delivery systems. Several OTC anesthetic sprays are formulated to deliver the drug through a metered-dose administration. Metered-dose delivery systems deliver lidocaine and prilocaine in base form without organic solvents. Such drugs can be easily removed before vaginal penetration, thus circumventing the need for a condom that most patients find uncomfortable. Hence, such advanced formulations are likely to boost the future growth of the global PE therapeutics market

The following factors are likely to contribute to the growth of the premature ejaculation therapeutics market during the forecast period:
•High Demand for Topical Drug Therapies for PE Treatment
•Low Effectiveness of Non-pharmacological PE Treatment
•Increasing Awareness Campaigns and Initiatives for PE Treatment
•Advances in PE Drug Formulation Technology

The study considers the present scenario of the premature ejaculation therapeutics market and its market dynamics for the period 2019?2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The study offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent companies operating in the market.

Premature Ejaculation Therapeutics Market: Segmentation

This research report offers a detailed segmentation by drugs, ROA, and geography. The SSRIs segment is likely to retain its market dominance during the forecast period. SSRIs are considered as effective drugs for the treatment of PE, and they majorly include paroxetine, sertraline, fluoxetine, citalopram, escitalopram, and dapoxetine. Several evidence-based studies have demonstrated the safety and efficacy of SSRIs in delaying ejaculation, which ensures their role as first-line agents for the treatment of lifelong and acquired PE. The growth of the segment is likely to be facilitated by an increase in the number of countries gaining approval for the use of Priligy. The increased recommendation of SSRIs by healthcare professionals is one of the key factors for the growth of the segment worldwide.
The increase in the share of the PDE5 inhibitors segment can be mainly attributed to the brand value of existing PDE5 inhibitor drugs, which facilitate high uptake among patients, especially for self-management. Anesthetic agents have proved effective and are generally tolerated for patients with PE. Several topical anesthetics are inexpensive and readily available from pharmacies, thereby allowing them an easy medication to buy. The segment is likely to witness higher CAGR during the forecast period than other drug therapies. The expected launch of new licensed/unlicensed OTC products worldwide is the prime factor enhancing growth.

Oral therapeutics consists of tablets, capsules, solutions, and suspensions. Several oral agents, specifically SSRIs, tramadol, and dapoxetine, have proven effective and safe for the treatment of PE. Hence, several HCPs are recommending oral therapeutics as a primary treatment option to manage premature ejaculation. A daily dose of oral therapies has exhibited improved and enhanced efficacy over topical therapies. Therefore, the demand for oral therapeutics is increasing at a steady-state worldwide. Moreover, the growing pervasiveness of PE and the increasing uptake of generic off-label medications are the key factors enabling the growth of the oral ROA segment.

Topical medications refer to the drugs that are applied to the skin and include creams, gels, sprays, powders, emulsion, solutions, and ointments. These drugs are often used as “a needed option” for efficient management of PE and erectile dysfunction. Therefore, the segment accounts for a smaller share than oral therapeutics. Easy availability of several topical medicines at multiple sales channels acts as one of the key factors, which boosts the product uptake of topical therapies in the vast majority of patients.

Market Segmentation by Drug Class
•SSRIs
•PDE5 Inhibitors
•Anesthetic Agents
•Others
Market Segmentation by ROA
•Oral PE therapeutics
•Topical PE therapeutics

Insights by Geography
North America is the major revenue contributor to the global premature ejaculation therapeutics market. The presence of a large disease population, coupled with better access to healthcare, especially OTC drugs, and increased focus on sexual wellness products is the primary factor for high shares. The strong presence of key vendors is also another reason for high product uptake in the region.

The presence of major vendors, better disease awareness, high healthcare spending on sexual wellbeing is the primary factor for high market share in this region. Germany, the UK, France, Italy, and Spain are the major revenue contributors. The increasing treatment-seeking population will mainly drive the market in Europe due to improved PE awareness and increased patient focus on healthy sexual well-being.

A low treatment-seeking population associated with social stigma in select regions, lack of awareness, and comparatively less access to healthcare services, especially in developing countries, are few factors that limit the growth of the market in this region. Japan, India, China, Australia, and South Korea are the major revenue contributors in the region.

Market Segmentation by Geography
•Europe
oSpain
oGermany
oItaly
oFrance
oUK
•North America
oUS
oCanada
•APAC
oSouth Korea
oChina
oJapan
oAustralia
oIndia
•Latin America
oBrazil
oArgentina
oMexico
•MEA
oTurkey
oSaudi Arabia
oSouth Africa
oIran

Insights by Vendors

The global premature ejaculation therapeutics market is fairly fragmented and is characterized by the presence of both pharmaceutical companies and generic manufacturers offering off-label branded drugs and generics. Vendors are offering off-label drugs, generic versions, and OTC topical anesthetic agents. Companies offering topical anesthetic drug formulations are gaining widespread popularity than manufacturers offering oral PE therapeutics. Pfizer, Bayer, Eli Lilly and Company, and GlaxoSmithKline are also being used as off-label drugs. Therefore, these global players have a significant presence in the market as physicians, especially in select countries such as the US, Germany, and Japan and are prescribing popular brands such as Paxil, Zoloft, Viagra, Levitra, and Cialis as off-label drugs. However, due to their high cost, a broad majority of physicians worldwide are recommending low-cost generic versions of these popular prescription drugs. Therefore, the market has witnessed the entry of many generic manufacturers offering generic drugs of the patent expired drugs at a low price.

Key Vendors
•Absorption Pharmaceuticals
•Innovus Pharmaceuticals
•Pfizer
•Plethora Solutions Holdings
Other Vendors
•Bayer
•Eli Lilly and Company
•GlaxoSmithKline
•MidasCare
•Momentum Management
•Pound International
•Reckitt Benckiser Group
•Recordati
•Royalty Pharma
•Shibari
•The Menarini Group

Key Market Insights
The analysis of the premature ejaculation therapeutics market provides sizing and growth opportunities for the period 2020–2025.
•Provides comprehensive insights on the latest industry trends, forecast, and growth drivers in the market.
•Includes a detailed analysis of growth drivers, challenges, and investment opportunities.
•Delivers a complete overview of segments and the regional outlook of the market.
•Offers an exhaustive summary of the vendor landscape, competitive analysis, and key strategies to gain competitive advantage.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off

($4250)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Rotavirus Infections - Pipeline Review, H1 2020

  • $ 2000
  • April 2020
  • 55 pages

Rotavirus Infections - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Rotavirus Infections - Pipeline Review, H1 2020, provides an overview of the Rotavirus ...

Vaccines Markets in China $ 4000 May 2020


ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on